PFIZER INC — Director's Dealing 2018

Jan 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PFIZER INC (PFE)
CIK: 0000078003
Period of Report: 2017-12-29

Reporting Person: YOUNG JOHN D (Group President)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-12-29	Common Stock	A	55218.0000	$0.0000	Acquired	179700.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-12-29	Phantom Stock Units SSP	$	A	11.0000	Acquired		Common Stock (11.0000)	Direct
2017-12-29	Stock Appreciation Rights	$36.2200	A	343053.0000	Acquired	2022-12-29	Common Stock (343053.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	1592.0000	Indirect
Common Stock	1410.0000	Indirect

Footnotes

F1: The reported transaction constitutes the grant of restricted stock units which will vest one third on each of the second, third and fourth anniversaries of grant provided he is continuously employed by Pfizer through the respective anniversaries.

F2: Each unit represents one phantom share of common stock.

F3: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time.

F4: The stock appreciation rights will settle on the fifth anniversary of the grant date (December 29, 2022) subject to both of the following requirements being met: (a) the reporting person remains continuously employed by Pfizer through the third anniversary of the grant date (December 29, 2020) and (b) Pfizer's total shareholder return is at least 25% or higher on average for 30 consecutive trading days anytime within the five-year performance period (which ends on December 29, 2022).